Nutramax Laboratories Inc v. Rowlo LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Nutramax Laboratories, Inc. and Nutramax Laboratories Veterinary Sciences, Inc. (South Carolina)
  • Defendant: Rowlo, LLC and Rowlo Capital US, Inc. (Wyoming)
  • Plaintiff's Counsel: Alston & Bird LLP
• Case Identification: 1:26-cv-01736, N.D. Ga., 03/31/2026
• Venue Allegations: Plaintiff alleges venue is proper because Defendant has a regular and established place of business in the district, commits acts of infringement in the district, and has previously sought to transfer other litigation to the district.
• Core Dispute: Plaintiff alleges that Defendant's calming chew supplements for dogs infringe two patents related to synergistic combinations of natural ingredients for reducing anxiety in mammals.
• Technical Context: The technology is in the field of animal nutraceuticals, specifically using combinations of plant extracts, amino acids, and proteins to achieve anxiolytic (anti-anxiety) effects as an alternative to synthetic pharmaceuticals.
• Key Procedural History: The complaint references a prior trademark dispute between the parties in which a court found Defendant's keyword advertising practices violated a settlement agreement. The complaint also notes that Plaintiff sent a cease-and-desist letter approximately one month before filing suit, putting Defendant on actual notice of the asserted patents.

Case Timeline

Date	Event
2015-08-31	Priority Date for U.S. Patent Nos. 10,335,384 and 12,194,011
2019-07-02	U.S. Patent No. 10,335,384 Issues
2025-01-14	U.S. Patent No. 12,194,011 Issues
2026-02-25	Plaintiff sends pre-suit notice letter to Defendant regarding infringement
2026-03-11	Defendant's counsel acknowledges receipt of notice letter
2026-03-31	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,335,384 - "Compositions Comprising Magnolia, Phellodendron, Theanine and/or Whey Protein"

• Issued: July 2, 2019

The Invention Explained

• Problem Addressed: The patent background describes how anxiety, fear, and stress contribute to significant behavioral problems in animals, and notes that common synthetic drug treatments can cause undesirable side effects such as sedation and lethargy '384 Patent, col. 1:20-2:6
• The Patented Solution: The invention is an anxiolytic composition that provides a "multi-modal approach" by combining several natural ingredients: L-theanine, a whey protein, an extract of magnolia, and an extract of phellodendron '384 Patent, col. 3:9-15 The patent posits that this combination works synergistically to manage anxiety by influencing multiple neurotransmitters, such as GABA and serotonin, without causing extreme sleepiness '384 Patent, abstract '384 Patent, col. 5:1-11
• Technical Importance: The claimed invention provides a potential alternative to single-mechanism synthetic drugs by using a combination of nutritional and herbal supplements to manage animal anxiety.

Key Claims at a Glance

• The complaint asserts infringement of independent claim 1 and dependent claims 3-7 and 9-11 Compl. ¶61
• Independent Claim 1 requires:
  • An anxiolytic composition, comprising a combination of L-theanine, a whey protein, an extract of magnolia, and an extract of phellodendron
  • provided in amounts synergistically effective to modulate one or more neurotransmitters.
• The complaint reserves the right to assert additional claims Compl. ¶66

U.S. Patent No. 12,194,011 - "Compositions Comprising Theanine, Magnolia, and Phellodendron"

• Issued: January 14, 2025

The Invention Explained

• Problem Addressed: Similar to the '384 Patent, the '011 Patent addresses the need for effective, non-sedating treatments for anxiety and stress-related behavioral disorders in animals '011 Patent, col. 1:24-2:10
• The Patented Solution: This invention claims an anxiolytic composition based on the synergistic combination of L-theanine with magnolia and phellodendron extracts '011 Patent, abstract Unlike the lead claim of the '384 Patent, this patent's core claims do not require the presence of a whey protein, focusing instead on the synergy between the other components to modulate brain neurotransmitters like glutamate and GABA '011 Patent, col. 5:1-14
• Technical Importance: The invention covers a specific formulation of natural extracts and an amino acid for managing animal anxiety, broadening the scope of protection to compositions that may not include a whey protein component.

Key Claims at a Glance

• The complaint asserts infringement of independent claims 1 and 13, as well as numerous dependent claims Compl. ¶70
• Independent Claim 1 requires:
  • An anxiolytic composition, comprising a combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron
  • in amounts synergistically effective to modulate one or more neurotransmitters.
• The complaint reserves the right to assert additional claims Compl. ¶75

III. The Accused Instrumentality

Product Identification

• The "Wuffes Calming Chews" Compl. ¶3

Functionality and Market Context

• The Accused Products are supplements sold to relieve stress and anxiety in dogs Compl. ¶3 The complaint alleges they contain a combination of L-Theanine, Relora® (identified as a blend of magnolia and phellodendron extracts), and dried whey Compl. ¶37 Specifically, each chew is alleged to contain 35 mg of L-Theanine and 75 mg of Relora® Compl. ¶37 The complaint alleges that Defendant markets the Accused Products as a functional equivalent to Plaintiff's Solliquin® product and began selling them after observing the success of Plaintiff's products Compl. ¶3 A screenshot from Defendant's website shows marketing materials that reference a clinical study on Plaintiff's Solliquin® product to support the effectiveness of the Accused Products Compl. p. 13

IV. Analysis of Infringement Allegations

'384 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An anxiolytic composition, comprising a combination of L-theanine, a whey protein, an extract of magnolia, and an extract of phellodendron...	The Wuffes Calming Chews are alleged to contain L-Theanine, dried whey, and Relora®, which is described as a blend of extracts of magnolia and phellodendron.	¶37	col. 3:32-37
...provided in amounts synergistically effective to modulate one or more neurotransmitters.	Defendant allegedly advertises that the ingredients have a "combined effect to reduce stress and promote calm" and are formulated at "meaningful doses" to be effective.	¶42; ¶46	col. 5:27-33

• Identified Points of Contention:
  • Technical Question: A central factual question will be whether the specific formulation of ingredients in the Wuffes Calming Chews is, in fact, "synergistically effective." The complaint relies heavily on Defendant's own advertising, which claims a "combined effect," as evidence of this limitation Compl. p. 16 The dispute may focus on whether this marketing language is sufficient proof of synergy or if independent scientific evidence demonstrating an effect greater than the sum of the parts is required.
  • Scope Question: The analysis may question whether the "dried whey" allegedly present in the accused product meets the "whey protein" limitation of the claim Compl. ¶37

'011 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An anxiolytic composition, comprising a combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron...	The Wuffes Calming Chews are alleged to contain L-Theanine and Relora®, a blend of magnolia and phellodendron extracts.	¶37	col. 13:20-24
...in amounts synergistically effective to modulate one or more neurotransmitters.	As with the '384 Patent, the complaint points to Defendant's advertising of a "combined effect" and reliance on studies of Plaintiff's synergistic product to support this element.	¶38; ¶42	col. 5:1-14

• Identified Points of Contention:
  • Technical Question: As described above for the '384 Patent, the key dispute will likely center on the evidentiary standard for proving the "synergistically effective" limitation. A screenshot from Defendant's website provides instructions for administering the chews at "meaningful doses" to achieve a calming effect, which Plaintiff presents as an acknowledgement of the claimed synergy Compl. p. 17

V. Key Claim Terms for Construction

• The Term: "synergistically effective"
• Context and Importance: This term appears in the asserted independent claims of both patents and is the primary technical limitation at issue. The entire infringement theory rests on whether the accused combination of ingredients produces an effect greater than the sum of its individual components. The complaint alleges Defendant admits to this property through its marketing Compl. ¶38 Compl. ¶43
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification provides a general definition: "synergy refers to the effect wherein a combination of two or more components provides a result which is greater than the sum of the effects produced by the agents when used alone" '384 Patent, col. 5:30-33 This could support a construction that does not require a specific, quantifiable biochemical outcome.
  • Evidence for a Narrower Interpretation: The patent details experiments showing synergistic effects on specific neurotransmitters like GABA and serotonin '384 Patent, FIGS. 1-2 '384 Patent, col. 10:1-28 A party could argue that "synergistically effective" requires proof of these specific types of modulation, rather than just an observed behavioral calming effect.

VI. Other Allegations

• Indirect Infringement: The complaint alleges inducement by asserting that Defendant's instructions, marketing materials, and other documentation encourage customers to use the Accused Products in an infringing manner (i.e., administering them to achieve the patented anxiolytic effect) Compl. ¶62 Compl. ¶71 The complaint also pleads contributory infringement, alleging the Accused Products are not staple articles of commerce and are especially adapted for infringing use Compl. ¶63 Compl. ¶72
• Willful Infringement: The complaint alleges willfulness based on both pre-suit and post-suit knowledge. It alleges Defendant, as a direct competitor, knew or should have known of the patents, particularly since it was aware of Plaintiff's Solliquin® product line, which is marked with the patent numbers Compl. ¶53 Compl. ¶55 More directly, the complaint alleges Defendant received actual notice of the patents and its infringement via a letter dated February 25, 2026, over a month before the lawsuit was filed Compl. ¶48 Compl. ¶64

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim construction: how will the court define "synergistically effective"? The case may turn on whether this term requires objective, scientific proof of specific neurotransmitter modulation as detailed in the patent specification, or if it can be satisfied by evidence of a general anxiolytic behavioral outcome, particularly when supported by the defendant's own advertising.
• A key evidentiary question will be one of admissions versus proof: can the plaintiff establish infringement of the "synergistically effective" limitation primarily through the defendant's marketing claims, which promote a "combined effect" and rely on studies of the plaintiff's own patented product? Or will the plaintiff be required to present its own laboratory testing of the accused product to factually demonstrate the synergistic mechanism?